- Home
- SSM vs GTBP Comparison
SSM vs GTBP Comparison
Compare SSM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSM | GTBP |
|---|---|---|
| Founded | N/A | 1965 |
| Country | Germany | United States |
| Employees | 43 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SSM | GTBP |
|---|---|---|
| Price | $7.23 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8K | ★ 980.3K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.34 | $0.40 |
| 52 Week High | $10.47 | $3.73 |
Technical Indicators
Market Signals| Indicator | SSM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 37.31 |
| Support Level | $6.70 | $0.41 |
| Resistance Level | $7.50 | $0.59 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 63.51 | 18.95 |
Price Performance
Historical ComparisonAbout SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.